Rapid Detection of Pseudomonas Aeruginosa in Bronchoalveolar Lavage Fluid Using Label-free Single-particle Imaging Technology and Assessment of Post-treatment Efficacy in Patients With Pseudomonas Aeruginosa Infection

Launched by THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIVERSITY · May 22, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to quickly detect a type of bacteria called Pseudomonas aeruginosa in a special fluid collected from the lungs of patients. The researchers will use advanced imaging technology to closely examine this fluid, which helps them identify the bacteria based on its size, shape, and movement. The goal is to diagnose infections faster and assess how well antibiotics are working by comparing samples taken before and after treatment.

To be eligible for this study, participants need to be at least 18 years old and have already tested positive for Pseudomonas aeruginosa in their lung fluid. Unfortunately, those under 18 or over 90, as well as pregnant or breastfeeding individuals, cannot participate. If you join the trial, you can expect to provide lung fluid samples and undergo assessments to help researchers understand the effectiveness of the treatment for this type of infection. This study is not yet recruiting participants, but it aims to improve how doctors diagnose and treat these infections in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18 years and above
• • After admission, Pseudomonas aeruginosa was cultured in bronchoalveolar lavage fluid or lower respiratory tract aspirates
• Exclusion Criteria:
• • Age under 18 years old or over 90 years old
• • Pregnancy, lactation period -